We are happy to announce and welcome Kurt Stoeckli to the team as President NDA Advisory Services.
Kurt brings significant experience from leadership positions in the pharmaceutical industry and has extensive expertise in the areas of immuno-oncology, autoimmune diseases and tolerogenic vaccination. His experience also spans medical devices and advanced digital e-health platforms.
As President of NDA Advisory Services Ltd, closely supported by Prof. Steffen Thirstrup, Kurt will manage the operations, strategy and development of the NDA Advisory Board, including business development, sales, marketing and service development. His intimate understanding of the working conditions in large pharmaceutical, as well as small biotech companies, will enable him to ensure close interactions and a rapid response to the shifting conditions that these companies are facing.
The NDA Advisory Board comprises some of the most well-known names in the industry, many of whom have been involved in designing the regulatory and HTA systems in place today. Together, they provide strategic advice and unbiased second opinions to pharmaceutical clients during part of, or the complete end-to-end drug development life cycle. This also includes support and advice during interaction with regulatory agencies, be it at scientific advice, during review of a marketing authorisation application or at any stage post-authorisation.
Johan Strömquist, CEO of NDA Group, commented on the appointment:
“The NDA Advisory Board is one of a kind – no other professional body comes as close to reflecting the current opinions and practices of the world’s regulatory and reimbursement agencies. I am delighted to welcome Kurt to our team. His experience, extensive network and industry reputation will break barriers and help us ensure that the best products get the attention they deserve. I very much look forward to working with him to help bring more good medicines to people all over the world.”
Kurt is joining NDA from Glenmark Switzerland where he was CEO and the groups global CSO. Prior to this he headed up the Biologics Division at Sanofi as Group VP & Global Head.
“Having Kurt on board is very exciting. He brings exactly the right blend of expertise and connectivity that is so important for us to have maximum impact on development of important therapies. His leadership experience and track record of launching new and bold initiatives will also be very welcome to our Advisory Board as we prepare to take the next step in our evolution.”
To learn more about the how the NDA Advisory board experts can support you and your drug development challenges click here
Advisory Board President